1   **Airway obstruction, serum vitamin D and mortality in a 33-year follow-up**

2   **study**

3

4   Tiina Mattila, MD[1,2,3]

5   Tuula Vasankari MD, PhD[4,5]

6   Harri Rissanen, MSc[3]

7   Paul Knekt, PhD[3]

8   Laura Sares-Jäske, MSc[3]

9   Tuija Jääskeläinen, MSc[3]

10   Markku Heliövaara, MD, PhD[3]

11   [1]Department of Pulmonary Diseases, Heart and Lung Center, Helsinki University Hospital,

12   Meilahti Triangle Hospital, 6th floor, PO Box 372, 00029 HUS, Helsinki, Finland.

13   [2]Doctoral Programme in Clinical Research, University of Helsinki, Helsinki, Finland.

14   [3]National Institute for Health and Welfare, PO Box 30, 00271 Helsinki, Finland.

15   harri.rissanen@thl.fi, paul.knekt@thl.fi, laura.sares-jaske@thl.fi, tuija.jaaskelainen@thl.fi,

16   markku.heliovaara@thl.fi

17   [4]University of Turku, Division of Medicine, Department of Pulmonary Diseases and Clinical

18   Allergology, Turku University Hospital and University of Turku, PO Box 52 (Hämeentie 11),

19   20521 Turku, Finland. tuula.vasankari@utu.fi

20   [5]Finnish Lung Health Association (FILHA), Filha ry, Sibeliuksenkatu 11 A 1, 00250

21   Helsinki, Finland.

22

23   **Correspondence**: Tiina Mattila, Helsinki University Hospital, Department of Pulmonary

24   Diseases, Meilahti Triangle Hospital, 6th floor, PO Box 372, 00029 HUS, Helsinki, Finland.

25   E-mail: tiina.m.mattila@fimnet.fi, tel: +358 50 361 2512. ORCID ID: 0000-0001-8466-985X

26   **Running head:** Vitamin D, airway obstruction and mortality.

31   **Word count**: abstract: 211 words, text: 2641 words, references: 39, tables: 4

32

33
34
35

36

Abstract

Background and objective: Chronic obstructive pulmonary disease and low vitamin D status predict mortality, but their combined effect on mortality remains inconclusive. We aimed to investigate a joint effect of airway obstruction and vitamin D status on mortality in a nationally representative cohort.

Methods: We analysed data of 6676 Finnish adults participating between 1978 and 1980 in a national health examination survey, undergoing spirometry and having all necessary data collected. We followed them up in national registers through record linkage until 31 December 2011. We categorised the subjects with obstruction using the lower limit of normal (LLN) and the measured serum 25-hydroxyvitamin-D (s-25(OH)D) into tertiles.

Results: Both obstruction and low s-25(OH)D independently predicted mortality in a multivariate model adjusted also for age, sex, smoking, education, leisure physical activity, body mass index, asthma and serum C-reactive protein. However, a statistically significant (p = 0.007) interaction emerged: the adjusted mortality HRs (95% CI's) for s-25(OH)D in tertiles among the subjects without and with obstruction were 1.00 (lowest), 0.96 (0.87–1.05) and 0.89 (0.81–0.98); and 1.00, 0.96 (0.71–1.31) and 0.57 (0.40–0.80), respectively.

Conclusions: In conclusion, obstruction and low s-25(OH)D predict mortality independently of each other. Our findings suggest that low vitamin D status might be particularly detrimental among subjects with obstruction.

Introduction

Low vitamin D status and chronic obstructive pulmonary disease (COPD) are common underdiagnosed conditions worldwide. Inadequate exposure to sunlight and an insufficient intake from dietary sources induces a low vitamin D status, generally measured as serum 25-hydroxyvitamin-D (s-25(OH)D) concentrations (<30 nmol/L determined as deficiency). The prevalence of s-25(OH)D deficiency is currently up to 30% in Europe and 0.6% in Finland, yet over 30 years ago >20% of our study population suffered from a low s-25(OH)D (1-5). In COPD, a progressing airway obstruction primarily caused by smoking leads to early death. Globally, COPD prevalence is 10.1%, falling to 4.3% and 3.1%, respectively, among Finnish men and women (6-8).

Previous studies have shown both associations between COPD and low s-25(OH)D and between decreasing lung function measures and 25(OH)D concentrations (1,9-11). However, the link between COPD and vitamin D metabolism remains unconfirmed. As such, a low s-25(OH)D evidently plays a role in regulating inflammatory reactions in COPD (1,3,12). Low s-25(OH)D and COPD are associated with similar factors, such as ageing, a low socioeconomic status, smoking, physical inactivity and chronic diseases (1,3,6,13,14). Yet, limited longitudinal data exist on the association between COPD and low s-25(OH)D (12).

Low s-25(OH)D and COPD predict premature death—COPD by decreasing lung function and the s-25(OH)D by decreasing concentration (6,13-18). Whether low s-25(OH)D has a similar or different association with mortality in subjects with COPD than in general population remains less studied and inconclusive (19-21).

Thus, we aimed to analyse whether a low s-25(OH)D confounds or modifies the association between airway obstruction and mortality during a long follow-up.

79

Material and methods

81

Study population

The Mini-Finland Health Survey, a population-based nationally representative health examination survey, consists of a two-stage cluster performed between 1978 and 1980 (22). In all 40 nationally representative areas with 40 000 to 60 000 subjects living on them were selected for inclusion in the first stage; and a representative sample of Finnish adults (3637 men and 4363 women) aged 30 to 91 from each area was selected from the population register in the second stage. Each subject in the population of each area had an equal probability for selection (probability proportional to size sampling). From this sample, 7217 (90%) subjects participated in the survey. Our study included 6676 subjects (3091 men and 3585 women) for whom was collected all relevant health information and who underwent a comprehensive health examination, including spirometry (22-25).

93

Measurements and definition of determinants

Laboratory technicians with special training performed spirometry using a Vitalograph spirometer (Vitalograph Ltd., Buckingham, England) following standard guidelines and instructions. Technicians presented the test procedure individually to each subject. Ideally, each participant produced minimum two spirometry curves, as consistent as possible, reaching an adequate and high-quality forced expiratory volume in 1 s (FEV_1) and forced vital capacity (FVC). The FEV_1/FVC was determined using the highest readings for FEV_1 and FVC from

101 the technically acceptable measurements for the air temperature and pressure, saturated with

102 water vapour (BTPS) values (spirometry technique used in Mini-Finland Health Survey).

103 Spirometry was performed without bronchodilation (22,23,25).

104 Individual lung function results were calculated using the Global Lung Function Initiative

105 (GLI) reference values which were derived from the spirometry records of 97,759 multi-

106 ethnic, healthy non-smokers aged 3 to 95. The GLI reference values were determined for four

107 separate ethnic groups, and we only applied the reference values for Caucasians. Subjects

108 with FEV_1/FVC values below the lower limit of normal (LLN) using reference values were

109 classified as having airway obstruction while others did not have obstruction (26,27).

110 Height and weight were measured. Body mass index (BMI) (weight (kg)/height² (m²)) was

111 used as a measure of relative weight. Age, sex, leisure physical activity and educational levels

112 were collected through a basic questionnaire. Leisure physical activity was determined

113 through questions on the frequency, intensity and duration of physical activity and further

114 categorized as inactive (little physical exercise), occasionally active (exercise alongside some

115 hobbies or irregular exercise) and regularly active (regular exercise). The completed number

116 of years of schooling classified educational levels in basic (<8 years), intermediate (8–12

117 years) and higher (>12 years) (22-25).

118 A standard interview inquired smoking habits, and these were categorized as never, former

119 and current smokers. Former smokers had quit smoking minimum one month before the

120 baseline survey. All subjects who had smoked at least one pipe, cigar or cigarette daily or

121 almost daily during the year before the survey were categorised as current smokers. Current

122 smokers were further categorized into two groups based on the number of daily smoked

123 cigarettes: 1 to 19 and ≥20 cigarettes (22-25).

124 Fasting blood samples were taken during the health examination and stored frozen at −20°C.

125 s-25(OH)D concentration was determined in 2003 using radioimmunoassay (DiaSorin, Inc.,

126 Stillwater, Minnesota, USA). The inter-assay coefficient of variation for s-25(OH)D

127 determination was 7.80% at a mean level of 47.3 nmol/L ($n = 167$) and 9.12% at 131.3

128 nmol/L ($n = 135$). The proportion of quality-control samples was 13.5% (5,28). In this study,

129 no single cut-off limit was used to define low s-25(OH)D. We classified s-25(OH)D

130 concentrations into tertiles: 5–32 nmol/L, 33–48 nmol/L and 49–180 nmol/L; the

131 concentrations approximated international definitions for vitamin D deficiency (<30 nmol/L)

132 and insufficiency (30–49.9 nmol/L) (4).

133 In Finland, situated geographically between the latitudes 60°N and 70°N, biologically

134 effective ultraviolet B irradiation producing vitamin D through the skin by sunshine is only

135 possible during the summer months. When our baseline study was performed, s-25(OH)D

136 concentrations were higher between May and October (2,5). Yet, baseline examinations were

137 conducted during different seasons. Therefore, we divided subjects into two seasonal groups:

138 winter (November–April) and summer (May–October).

139 Serum C-reactive protein (CRP) concentration was determined between 2003 and 2005 using

140 a latex turbido-metric immunoassay (Olympus AU 400 analyser system for clinical chemistry,

141 Wako Chemicals, Neuss, Germany), at a detection limit of 0.06 mg/L. The measured CRP

142 levels were categorised as 0.04–0.99 mg/L, 1.00–1.99 mg/L and ≥2.00 mg/L (22,24).

143 Subject´s chronic disease history and their overall health status was inquired in the basic

144 questionnaire. For those subjects who had any abnormal findings from the examination or

145 questionnaires, a specially trained physician performed a standardised physical examination

146 (22-24). The physician diagnosed asthma on the basis of medical history, symptoms and

147 physical status applying preset criteria (22-25).

148

149 *Follow-up*

150 We continuously followed mortality from Statistics Finland using the subjects´ individual

151 identification numbers to track participants from baseline examination through 31 December

152 2011 (29).

153

154 *Statistical analysis*

155 We constructed our models to analyse associations between obstruction and low s-25(OH)D

156 primarily based on previous Finnish publications. As such, we previously analysed factors

157 which were associated with obstruction in the same population sample (25) and others with s-

158 25(OH)D in another Finnish data set (30,31). Factors which were associated with obstruction

159 and s-25(OH)D previously included age, education (in years), leisure physical activity, BMI

160 and smoking history. In addition, CRP and sex were associated with obstruction and s-

161 25(OH)D in this material, and a history of asthma represented a possible confounding factor

162 for obstruction. All these variables appeared relevant to our study; thus, we included them all

163 in our analysis here. Additionally, we analysed the modifying effect of season of s-25(OH)D

164 blood sampling (5,30,31).

165 We analysed the cross-sectional associations between obstruction and baseline characteristics

166 using logistic regression, expressing results as model-adjusted odds ratios (ORs) with 95%

167 confidence intervals (CIs). We analysed the strength of the associations of obstruction and s-

168 25(OH)D with mortality in the cohort study design using Cox's proportional hazards

169 regression model. The results were expressed as model-adjusted hazard ratios (HRs) with

170 95% CIs. We constructed three main models: adjusting for age and sex (1); further for

171 smoking (2); and finally also for leisure physical activity, education, BMI, asthma and serum

172 C-reactive protein (3, multivariate model), which were also considered potential confounding

173 factors. Whether s-25(OH)D, season of blood sample collection and obstruction modified the

174 effects of each other were examined by entering their first-degree interaction terms into the

175 multivariate models. Statistical significance was tested using the likelihood ratio test. Finally,

176 to explore the proportional hazards assumption of the Cox's model and to test the adequacy of

177 the long follow-up, we compared the results from the full model between the follow-up times

178 of 0–10 years, 11–20 years and >20 years from baseline. In addition, we also restricted the

179 follow-up experience to the years 2005 to 2011 to explore influence of the fortification of

180 food with vitamin D that was introduced in Finland in 2003. We analysed s-25(OH)D as both

181 categorical (tertiles) and ordinary-scaled variables throughout the study. All analyses were

182 performed using SAS System for Windows (version 9.3, SAS Institute, Inc., Cary, NC, USA)

183 and IBM´s SPSS (version 24).

184

185 *Ethical considerations*

186 The Mini-Finland Health Survey predated current legislation on ethics in medical research.

187 However, all participants were fully informed about the study, participated voluntarily and the

188 use of their information for medical research was explained to them. Agreeing to participate

189 in the baseline health examination was considered informed consent. Statistics Finland

190 approved the linkage of national mortality data to the survey data used here (29).

191 This study does not fall under the purview of laws regarding medical research, thus, the study

192 protocol does not violate any ethical considerations or standards, according to a statement

193   from the Medical Ethics Committee of the Hospital District of Helsinki and Uusimaa in

194   Finland (June 2013).

195

196   **Results**

197   Table 1 presents the baseline characteristics and their prevalence. At baseline, the cohort

198   included 311 (4.7%) subjects with obstruction. Mean FEV_1 was 2.1 l/s (standard deviation

199   (SD) 1.0) in obstructive and 3.3 l/s (SD 1.0) in non-obstructive subjects, while mean

200   concentrations of s-25(OH)D reached 39.1 nmol/L (SD 18.8) and 43.6 nmol/L (SD 19.5),

201   respectively.

202   We found an inverse association between obstruction and s-25(OH)D (Table 1). The season

203   of blood sample collection did not modify that association (p=0.68 for the interaction).

204   By the end of 2011, 3530 (52.9%) deaths in the study population occurred, while 247 (79.4%)

205   of the subjects with obstruction died. Obstruction and low s-25(OH)D independent of one

206   another predicted mortality (Table 2). HR (95% CI) for the subjects with obstruction was 1.46

207   (1.28–1.68) when those without obstruction were used as the reference, while for s-25(OH)D

208   from the lowest to highest tertile, HRs were 1 (reference), 0.92 (0.85–1.00) and 0.84 (0.78–

209   0.92), respectively. Low s-25(OH)D did not confound the association between obstruction

210   and mortality (Table 3).

211   A statistically significant interaction (p=0.007) emerged between obstruction and s-25(OH)D

212   tertiles when entered as a categorical variable: among subjects with obstruction HR (95% CI)

213   was 0.57 (0.40–0.80) in the third tertile, whereas among those without obstruction the

214   corresponding HR was 0.89 (0.81–0.98) (Table 4). The season of blood sample collection did

215 not further modify or confound the associations of obstruction and s-25(OH)D with mortality

216 (data not shown).

217 Finally, we used multivariate models to analyse the follow-up time strata of 0–10 years, 11–

218 20 years and >20 years from baseline. The primary findings remained largely unchanged (data

219 not shown). However, when the follow-up experience was restricted to the years 2005 to 2011

220 (21 deaths in 85 subjects with airway obstruction), the baseline s-25(OH)D did not anymore

221 predict mortality (p-value for trend 0.32); HRs from the lowest to highest tertile were 1

222 (reference), 0.90 (0.76–1.07) and 0.88 (0.74–1.05), respectively.

223

224 **Discussion**

225 In our study airway obstruction and low s-25(OH)D independent of each other predicted

226 mortality during the follow-up of 33 years. However, the association between low s-25(OH)D

227 and mortality was stronger in those with obstruction than others.

228 In accordance with previous studies, we observed an inverse cross-sectional association

229 between obstruction and s-25(OH)D, which was partly explained by other factors. COPD is

230 evidently associated with low s-25(OH)D (1,9-11,14). Previously, vitamin D supplementation

231 improved lung functions among ever-smokers with vitamin D-deficiency or COPD and

232 decreased COPD exacerbations (32,33). Yet, the association between COPD and low s-

233 25(OH)D is complex, multiple factors tend to confound it and previous findings appear

234 contradictory (1,12). COPD and low s-25(OH)D have both shown associations with both

235 chronic diseases and many factors predicting morbidity, such as ageing, smoking and reduced

236 physical activity (1,3,6,13,30,34,35). Furthermore, low s-25(OH)D and s-25(OH)D

237 metabolites might affect COPD pathophysiology and co-morbidities, such as osteoporosis,

238 cardiovascular diseases and respiratory infections (1,3,12,20).

239 In our study obstruction and low s-25(OH)D predicted mortality independently of each other

240 and independently of other confounding factors. Comparisons of the results between previous

241 studies and the present one are difficult because of the wealth of factors discussed above

242 (1,3,6,12,13,30,34,35). In two studies with follow-up times from 10 to 14 years, low s-

243 25(OH)D did not predict mortality among subjects with obstruction (19,20). Another study

244 adjusted for common cardiovascular risk factors revealed an association between low s-

245 25(OH)D and mortality among those with normal lung function (19). In a third study with an

246 18-year follow-up, low s-25(OH)D predicted mortality among the subjects with obstruction;

247 however, this resulted primarily from the higher age and more negative cardiovascular risk

248 factor profile of those with a low s-25(OH)D (21). In that study, the cut-off limit for the

249 lowest s-25(OH)D tertile was <50.9 nmol/L which was much higher than our cut-off limit of

250 <33 nmol/L.

251 In our study the association between low s-25(OH)D and mortality appeared pronounced

252 among the subjects with obstruction. Albeit statistically significant, this interaction may

253 result from chance alone because of small numbers of subjects. Nevertheless, if replicated in

254 future studies, intervention trials and therapeutic implications may prove justified.

255 Our study's strength lies in its continuous 33-year follow-up of a population sample

256 representing adult Finns from a national health examination survey with a 90% participation

257 rate (22,23). Specially trained expert professionals performed examinations using

258 standardised methods (22-24). The causes and dates of death were obtained from death

259 certificates signed by the physicians responsible for their care (22,29). An additional strength

260 lies in the naturally low s-25(OH)D in our study population; when the baseline survey was

261 executed, no vitamin D fortification was used and working outside in summertime under the

262 sun remained common (22,23). The use of vitamin D supplements complicates and confounds

263 analyses in newer datasets (1,3,12,30) whereas it rarely appeared among Finnish adults at the

264 time of our baseline survey. In addition, the concentration of s-25(OH)D remains stable in

265 long-term stored blood samples (36), although the 20 years between blood sampling and

266 analyses might affect the s-25(OH)D concentrations measured.

267 The small sample size is the primary limitation in our study—our material carried no

268 statistical power for more specific analyses. Therefore, such topics as the specific causes of

269 death and degree of obstruction remain unanalysed. This same material resulted in previous

270 publications regarding the influence of obstruction and s-25(OH)D, respectively, on

271 cardiovascular and coronary mortality and the severity of obstruction and all-cause mortality

272 (5,25,37). In addition, no bronchodilation test was performed; thus, we maybe have,

273 incorrectly, categorised some reversible obstructions as chronic. Unfortunately, we had no

274 data about COPD´s exacerbations and could, therefore, not consider this possible confounder.

275 Additionally, no absolute definitions for COPD, obstruction or low s-25(OH)D exist, although

276 clinicians use definitions and cut-off limits for both (2,4,6,27). Therefore, the results from

277 studies (this and others) may not be directly comparable, a problem previously observed

278 (3,10,37). There is remarkable seasonal and other variation in s-25(OH)D levels (38) but,

279 unfortunately, only one blood sample was taken in our study. An additional limitation appears

280 in the markedly improved s-25(OH)D among Finns between 2000 and 2011 resulting from

281 the vitamin D fortification policy initiated after 2003 (2) and changes in smoking habits.

282 However, the prevalence of obstruction remained unchanged in Finland between the Mini-

283 Finland (1978–1980) and Health 2000 Surveys (7,39). Furthermore, other baseline

284 characteristics may have changed during follow-up exerting some influence on our results.

285 This limitation typically accompanies cohort studies.

286

287 **Conclusions**

288 In conclusion, airway obstruction and low s-25(OH)D independently predict mortality; an

289 outcome which a physician should consider when treating high-risk groups. If not replicated

290 in future, the interaction we found for obstruction and low s-25(OH)D upon mortality does

291 not justify causal inference.

292

297

304

305 **Funding**

References:

308

309

310 (1) Kokturk N, Baha A, Oh YM, Young Ju J, Jones PW. Vitamin D deficiency: What does it
311 mean for chronic obstructive pulmonary disease (COPD)? a compherensive review for
312 pulmonologists. Clin Respir J 2016 December 07.

313 (2) Jaaskelainen T, Itkonen ST, Lundqvist A, Erkkola M, Koskela T, Lakkala K, et al. The
314 positive impact of general vitamin D food fortification policy on vitamin D status in a
315 representative adult Finnish population: evidence from an 11-y follow-up based on
316 standardized 25-hydroxyvitamin D data. Am J Clin Nutr 2017 June 01;105(6):1512-1520.

317 (3) Quint JK, Wedzicha JA. Is vitamin D deficiency important in the natural history of
318 COPD? Thorax 2010 March 01;65(3):192-194.

319 (4) Institute of Medicine Food and Nutrition Board. Dietary reference intakes for adequacy:
320 calcium and vitamin D. National Academies Press: Washington (DC), USA, 2011.

321 (5) Kilkkinen A, Knekt P, Aro A, Rissanen H, Marniemi J, Heliovaara M, et al. Vitamin D
322 status and the risk of cardiovascular disease death. Am J Epidemiol 2009 October
323 15;170(8):1032-1039.

324 (6) Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global
325 Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung
326 Disease 2017 Report: GOLD Executive Summary. Eur Respir J 2017 March 06;49(3):2017.
327 Print 2017 Mar.

328 (7) Vasankari TM, Impivaara O, Heliovaara M, Heistaro S, Liippo K, Puukka P, et al. No
329 increase in the prevalence of COPD in two decades. Eur Respir J 2010 October 01;36(4):766-
330 773.

331 (8) Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al.
332 International variation in the prevalence of COPD (the BOLD Study): a population-
333 based prevalence study. Lancet. 2007 Sep 1;370(9589):741-50.

334

335 (9) Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, et al. Vitamin
336 D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-
337 binding gene. Thorax 2010 March 01;65(3):215-220.

338 (10) Zhu M, Wang T, Wang C, Ji Y. The association between vitamin D and COPD risk,
339 severity, and exacerbation: an updated systematic review and meta-analysis. Int J Chron
340 Obstruct Pulmon Dis 2016 October 19;11:2597-2607.

341 (11) Afzal S, Lange P, Bojesen SE, Freiberg JJ, Nordestgaard BG. Plasma 25-hydroxyvitamin
342 D, lung function and risk of chronic obstructive pulmonary disease. Thorax 2014 January
343 01;69(1):24-31.

344 (12) Janssens W, Decramer M, Mathieu C, Korf H. Vitamin D and chronic obstructive
345 pulmonary disease: hype or reality? Lancet Respir Med 2013 December 01;1(10):804-812.

346 (13) Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, et al. Comorbidity,
347 systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013 September
348 01;107(9):1376-1384.

349 (14) Khaw KT, Luben R, Wareham N. Serum 25-hydroxyvitamin D, mortality, and incident
350 cardiovascular disease, respiratory disease, cancers, and fractures: a 13-y prospective
351 population study. Am J Clin Nutr 2014 November 01;100(5):1361-1370.

352 (15) Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S. Vitamin D deficiency
353 and mortality risk in the general population: a meta-analysis of prospective cohort studies.
354 Am J Clin Nutr 2012 January 01;95(1):91-100.

355 (16) Baughman P, Marott JL, Lange P, Martin CJ, Shankar A, Petsonk EL, et al. Combined
356 effect of lung function level and decline increases morbidity and mortality risks. Eur J
357 Epidemiol 2012 December 01;27(12):933-943.

358 (17) Ford ES, Zhao G, Tsai J, Li C. Vitamin D and all-cause mortality among adults in USA:
359 findings from the National Health and Nutrition Examination Survey Linked Mortality Study.
360 Int J Epidemiol 2011 August 01;40(4):998-1005.

361 (18) Gaksch M, Jorde R, Grimnes G, Joakimsen R, Schirmer H, Wilsgaard T, et al. Vitamin D
362 and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D
363 in 26916 individuals from a European consortium. PLoS One 2017 February
364 16;12(2):e0170791.

365 (19) Ford ES. Lung function, 25-hydroxyvitamin D concentrations and mortality in US adults.
366 Eur J Clin Nutr 2015 May 01;69(5):572-578.

367 (20) Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Fruekilde PB, Pedersen SS, et al.
368 Serum vitamin D in patients with chronic obstructive lung disease does not correlate with
369 mortality--results from a 10-year prospective cohort study. PLoS One 2013;8(1):e53670.

370 (21) Lee HM, Liu M, Lee K, Luo Y, Wong ND. Does low vitamin D amplify the association
371 of COPD with total and cardiovascular disease mortality? Clin Cardiol 2014 August
372 01;37(8):473-478.

373 (22) National Institute for Health and Welfare in Finland. Available at:
374 https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/population-studies/finnish-
375 mobile-clinic/mini-finland-health-survey. Accessed: October 25, 2017.

376 (23) Aromaa A, Heliövaara M, Impivaara O, et al. Health, functional limitations and need for
377 care in Finland. Basic results from the Mini-Finland Health Survey (in Finnish with English

378   Summary). Publications of the Social Insurance Institution 1989. Helsinki and Turku.
379   Available at: http://hdl.handle.net/10138/162843. Accessed: October 25 2017.

380   (24) Aromaa A, Heliövaara M, Knekt P, Reunanen A, Impivaara O, Maatela J. Cardiovascular
381   and respiratory survey methods. Part 2 (in Finnish with English summary). Publications of the
382   Social Insurance Institution 1985. Helsinki and Turku. Available at:
383   http://hdl.handle.net/10138/162384. Accessed: October 25 2017.

384   (25) Mattila T, Vasankari T, Kanervisto M, Laitinen T, Impivaara O, Rissanen H, et al.
385   Association between all-cause and cause-specific mortality and the GOLD stages 1-4: A 30-
386   year follow-up among Finnish adults. Respir Med 2015 August 01;109(8):1012-1018.

387   (26) Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative
388   strategies for lung function tests. Eur Respir J 2005 November 01;26(5):948-968.

389   (27) Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic
390   reference values for spirometry for the 3-95-yr age range: the global lung function 2012
391   equations. Eur Respir J 2012 December 01;40(6):1324-1343.

392   (28) Konstari S, Paananen M, Heliovaara M, Knekt P, Marniemi J, Impivaara O, et al.
393   Association of 25-hydroxyvitamin D with the incidence of knee and hip osteoarthritis: a 22-
394   year follow-up study. Scand J Rheumatol 2012 March 01;41(2):124-131.

395   (29) Statistics Finland. Causes of deaths. Available at: http://www.stat.fi/index_en.html,
396   http://www.stat.fi/til/ksyyt/2005/ksyyt_2005_2006-10-31_luo_002.html. Accessed: 2011.

397   (30) Jaaskelainen T, Knekt P, Marniemi J, Sares-Jaske L, Mannisto S, Heliovaara M, et al.
398   Vitamin D status is associated with sociodemographic factors, lifestyle and metabolic health.
399   Eur J Nutr 2013 March 01;52(2):513-525.

400   (31) Virtanen JK, Nurmi T, Voutilainen S, Mursu J, Tuomainen TP. Association of serum 25-
401   hydroxyvitamin D with the risk of death in a general older population in Finland. Eur J Nutr
402   2011 August 01;50(5):305-312.

403   (32) Sluyter JD, Camargo CA, Waayer D, Lawes CMM, Toop L, Khaw KT, et al. Effect of
404   Monthly, High-Dose, Long-Term Vitamin D on Lung Function: A Randomized Controlled
405   Trial. Nutrients 2017 December 13;9(12):10.3390/nu9121353.

406   (33) Zendedel A, Gholami M, Anbari K, Ghanadi K, Bachari EC, Azargon A. Effects of
407   Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study.
408   Glob J Health Sci 2015 January 14;7(4):243-248.

409   (34) World Health Organization WHO. Noncommunicable diseases and mental health.
410   Available at: http://www.who.int/nmh/events/ncd_action_plan/en. Accessed: October 25,
411   2017.

412   (35) Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens EJ, Kromhout D. Prevalence of
413   morbidity and multimorbidity in elderly male populations and their impact on 10-year all-

414   cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 2001
415   July 01;54(7):680-686.

416   (36) Agborsangaya C, Toriola AT, Grankvist K, Surcel HM, Holl K, Parkkila S, et al. The
417   effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D
418   and androstenedione. Nutr Cancer 2010;62(1):51-57.

419   (37) Mattila T, Vasankari T, Rissanen H, Knekt P, Puukka P, Heliovaara M. Airway
420   obstruction and the risk of myocardial infarction and death from coronary heart disease: a
421   national health examination survey with a 33-year follow-up period. Eur J Epidemiol 2017
422   July 07.

423   (38) Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of
424   serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12
425   months in an intervention study. Am J Epidemiol 2010 April 15;171(8):903-908.

426   (39) Jousilahti P, Borodulin K. Suomalaisten tupakointi vähenee. Tutkimuksesta tiiviisti 3 (in
427   Finnish). Publications of the National Institute for Health and Welfare: Helsinki, Finland,
428   2012.

429

Table 1

Baseline characteristics and their associations with airway obstruction (FEV$_1$/FVC below LLN) in the study population from the logistic regression analyses

Characteristics		Total (n)	Obstruction (n)[1]	OR[2]	95% Cl	OR[3]	95% Cl
Vitamin D status[4]	First tertile (5–32 nmol/L)	2177	131	1		1	
	Second tertile (33–48 nmol/L)	2284	101	0.79	0.59–1.08	0.93	0.70–1.23
	Third tertile (49–180 nmol/L)	2215	79	0.61	0.44–0.85	0.75	0.55–1.02
p (for trend)				0.001		0.07	
Age (in years)	Mean 50.5, SD ± 13.7[5]		311	1.67	1.50–1.88	1.66	1.45–1.89
p (for trend)				<0.001		<0.001	
Sex	Male	3091	207	1		1	
	Female	3585	104	0.38	0.30–0.48	0.58	0.43–0.79
p (for heterogeneity)				<0.001		<0.001	
Smoking	Never smoker	3690	92	1		1	
	Former smoker	1388	79	2.03	1.43–2.88	2.20	1.54–3.15
	Current smoker, 1–19 cigarettes/day	991	83	3.90	2.77–5.48	3.42	2.39–4.90
	Current smoker, ≥20 cigarettes/day	607	57	4.81	3.23–7.17	4.41	2.91–6.70
p (for heterogeneity)				<0.001		<0.001	
Asthma	No	6558	280	1		1	
	Yes	118	31	8.82	5.65–13.78	11.43	7.11–18.36
p (for heterogeneity)				<0.001		<0.001	
Leisure physical activity	Inactive	2349	155	1		1	
	Occasionally active	3279	133	0.65	0.51–0.82	0.78	0.61–1.01
	Regularly active	1048	23	0.36	0.23–0.57	0.51	0.32–0.82
p (for heterogeneity)				<0.001		0.009	
Educational level	Basic	4480	261	1		1	
	Intermediate	1431	33	0.48	0.33–0.70	0.51	0.35–0.75
	Higher	765	17	0.49	0.30–0.82	0.56	0.33–0.94
p (for heterogeneity)				<0.001		<0.001	
BMI	<20	310	32	1		1	
	20–24.99	2733	135	0.39	0.26–0.59	0.43	0.27–0.67
	25–29.99	2632	105	0.26	0.17–0.40	0.28	0.18–0.45
	30–34.99	826	32	0.26	0.15–0.44	0.26	0.15–0.45
	≥35	175	7	0.35	0.15–0.82	0.32	0.13–0.78
p (for trend)				<0.001		<0.001	
CRP[6]	0.04–0.99 mg/L	3180	107	1		1	
	1–1.99 mg/L	1528	77	1.26	0.93–1.71	1.22	0.89–1.68
	≥2.00 mg/L	1968	127	1.43	1.09–1.88	1.16	0.86–1.55
p (for trend)				0.01		0.35	

[1] FEV$_1$/FVC below LLN.

[2] Odds ratio (OR) with 95% confidence intervals (CIs), age adjusted for sex, sex adjusted for age and the other factors adjusted for age and sex.

[3] OR with 95% CIs in a multivariate model adjusted for all factors listed in this table.

[4] Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles
[5] SD, standard deviation; range 61, 30–91 years.
[6] Concentration of C-reactive protein.

430

Table 2

Associations between baseline characteristics and mortality from 1978–1980 through 31 December 2011

Characteristics		Deaths (n)	HR[1]	95% CI	HR[2]	95% CI
Obstruction[3]	No	3283	1		1	
	Yes	247	1.68	1.48–1.92	1.46	1.28–1.68
p (for heterogeneity)			<0.001		<0.001	
Vitamin D status[4]	First tertile (5–32 nmol/L)	1331	1		1	
	Second tertile (33–48 nmol/L)	1165	0.89	0.82–0.96	0.92	0.85–1.00
	Third tertile (49–180 nmol/L)	1034	0.77	0.71–0.84	0.84	0.78–0.92
p (for trend)			<0.001		<0.001	
Age	Years, ±1 SD	Mean 59.0, SD ± 12.2, Range 61[5]	4.42	4.23–4.63	4.49	4.28–4.71
p (for trend)			<0.001		<0.001	
Sex	Male	1759	1		1	
	Female	1771	0.54	0.51–0.58	0.63	0.58–0.68
p (for heterogeneity)			<0.001		<0.001	
Smoking	Never smoker	1845	1		1	
	Former smoker	748	1.12	1.02–1.23	1.12	1.01–1.23
	Current smoker, 1–19 cigarettes/day	563	1.86	1.68–2.06	1.72	1.55–1.91
	Current smoker, ≥20 cigarettes/day	374	2.73	2.41–3.09	2.35	2.06–2.67
p (for heterogeneity)			<0.001		<0.001	
Asthma	No	3456	1		1	
	Yes	74	1.05	0.83–1.32	0.95	0.75–1.20
p (for heterogeneity)			0.70		0.68	
Leisure physical activity	Inactive	1498	1		1	
	Occasionally active	1623	0.78	0.72–0.83	0.87	0.81–0.94
	Regularly active	409	0.69	0.62–0.77	0.87	0.78–0.98
p (for heterogeneity)			<0.001		<0.001	
Educational level	Basic	2750	1		1	
	Intermediate	559	0.87	0.79–0.95	0.92	0.84–1.01
	Higher	221	0.68	0.59–0.78	0.73	0.64–0.84
p (for heterogeneity)			<0.001		<0.001	
BMI	<20	138	1		1	
	20–24.9	1174	0.59	0.50–0.71	0.63	0.53–0.75
	25–29.9	1514	0.61	0.51–0.72	0.65	0.54–0.78
	30–34.9	576	0.74	0.62–0.90	0.74	0.61–0.89
	≥35	128	0.86	0.68–1.10	0.78	0.61–1.00
p (for trend)			0.005		0.196	
CRP[6]	0–0.99 mg/L	1234	1		1	
	1–1.99 mg/L	913	1.22	1.12–1.33	1.15	1.05–1.26
	≥2 mg/L	1383	1.67	1.54–1.80	1.46	1.35–1.59
p (for trend)			<0.001		<0.001	

[1] Hazard ratio (HR) with 95% confidence intervals (CIs), age adjusted for sex, sex adjusted for age and other factors adjusted for age and sex.

[2] HR with 95% CIs in a multivariate model adjusted for all factors listed in this table.

[3] FEV_1/FVC over or below LLN.

[4] Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles.

432

Table 3

Association between airway obstruction (FEV_1/FVC below LLN) and mortality[1] in variously adjusted models from 1978–1980 through 31 December 2011

Model adjusted for		HR[2]	95% CI
Age and sex	No obstruction[3]	1	
	Obstruction[3]	1.69	1.49–1.93
Age, sex, vitamin D status[4]	No obstruction[3]	1	
	Obstruction[3]	1.68	1.48–1.92
Age, sex, smoking history	No obstruction[3]	1	
	Obstruction[3]	1.53	1.34–1.74
Age, sex, smoking history, vitamin D status[4]	No obstruction[3]	1	
	Obstruction[3]	1.52	1.33–1.73
Full model[5], without vitamin D status[4]	No obstruction[3]	1	
	Obstruction[3]	1.46	1.27–1.67
Full model[5] with vitamin D status[4]	No obstruction[3]	1	
	Obstruction[3]	1.46	1.28–1.67

[1] There were 3283 deaths in subjects without obstruction and 247 in those with obstruction.

[2] Hazard ratio (HR) with 95% confidence intervals (CIs).

[3] FEV_1/FVC over or below LLN.

[4] Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles.

[5] Multivariate model adjusted for age, sex, smoking, obstruction, asthma, education (in years), leisure physical activity, BMI and CRP.

433

434 **Table 4**

435 Association between airway obstruction (FEV$_1$/FVC below LLN), vitamin D status and mortality from 1978–1980 through 31 December 2011

Characteristics	No obstruction				Obstruction			
Vitamin D status[1]	Total (n)	Deaths (n)	HR[2]	95% CI	Total (n)	Deaths (n)	HR[2]	95% CI
First tertile (5–32 nmol/L)	2046	1220	1		131	111	1	
Second tertile (33–48 nmol/L)	2183	1083	0.96	0.87–1.05	101	82	0.96	0.71–1.31
Third tertile (49–180 nmol/L)	2136	980	0.89	0.81–0.98	79	54	0.57	0.40–0.80
p-value for trend				0.002				0.002
p-values for interactions 'obstruction*vitamin D status'								
Vitamin D status as an ordinary scaled variable:				0.02				
Vitamin D status as a categorical variable:				0.007				

[1] Concentration of 25-hydroxyvitamin D (25(OH)D).

[2] HR with 95% CIs in multivariate model adjusted for age, sex, smoking, obstruction, asthma, education (in years), leisure physical activity, BMI and CRP.

437